Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415, France.
Vaccine. 2023 Aug 31;41(38):5490-5493. doi: 10.1016/j.vaccine.2023.07.071. Epub 2023 Aug 3.
This cohort study evaluated the protection against symptomatic Omicron BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to mRNA Original monovalent vaccines (Pfizer- BioNTech or Moderna). Individuals of ≥60 years old, who received a booster dose between 03/10/2022 and 06/11/2022, when both bivalent and monovalent vaccines were used in France, were included and matched according to the type of booster vaccine received. The outcome of interest was a positive SARS-CoV-2 RT-PCR or antigenic test associated to self-reported symptoms, ≥ seven days after receiving the booster dose. Data were analysed with a Cox Proportional-Hazards model adjusted for the presence of previous infection, age, sex, and the presence of medium risk comorbidities. A total of 136,852 individuals were included and followed for a median period of 77 days. The bivalent vaccine conferred an additional protection of 8 % [95 % CI: 0 %-16 %, p = 0.045] against symptomatic Omicron BA.5infection compared to the monovalent vaccines.
本队列研究评估了辉瑞-生物科技原始/BA.4-5 二价疫苗相对于 mRNA 原始单价疫苗（辉瑞-生物科技或 Moderna）对有症状的奥密克戎 BA.5 感染的保护作用。≥60 岁的个体，在 2022 年 3 月 10 日至 2022 年 6 月 11 日期间接受了加强针，当时法国同时使用了二价和单价疫苗，根据所接受的加强针类型进行匹配。主要结局是在接受加强针后≥7 天出现与自我报告症状相关的 SARS-CoV-2 RT-PCR 或抗原检测阳性。采用 Cox 比例风险模型对既往感染、年龄、性别和中等风险合并症的存在进行调整后分析数据。共纳入 136852 名患者，中位随访期为 77 天。与单价疫苗相比，二价疫苗对有症状的奥密克戎 BA.5 感染的额外保护作用为 8%[95%CI:0%-16%，p=0.045]。
